Age is the strongest risk factor for AD, so it suggests that AD variants in m116 may primarily have a role in accelerating microglial aging and may not have strong, direct effects on β-amyloid and Tau pathologies or cognitive decline beyond what is accounted for by advancing age. The gene discussed is MAPT; the disease is Alzheimer disease.